ICON Early Phase Services is looking for men and women who are overweight or have obesity but otherwise healthy for a clinical research study. This study is being done to test an investigational product for weight management. The study drug will be administered by subcutaneous injections.
The very first appointment will be the information session where you will be given information about the study. Please note, you do not have to fast for the information visit. You will have the opportunity to ask questions and receive further information on the study and you will also be given an informed consent form. No study procedures will be performed at this first appointment and no fasting is required for the information session appointment. After you receive information on the study and have the opportunity to ask your questions, you may either decline participation in the study or agree to participate and sign the study informed consent form. If you agree to participate in the study, the study staff will schedule with you a screening visit appointment and will provide you with the requirements for the screening visit, inform you about what procedures will be done at the screening visit and will discuss with you about what medical records and documents you should bring to the screening visit.
Please review the information below and determine whether you are interested in the study and would like to schedule your information session appointment.
Vital signs, physical examinations, ECGs, hormone level evaluation and drug and alcohol screens will be performed. Blood and urine samples will also be obtained during this study.
After the information session appointment and if you agree to participate in the study and sign the study informed consent, you will be invited and scheduled to complete a screening visit.
To determine if you fully qualify, it will be necessary to obtain blood samples after an 8-hour fast. You have the option of fasting for the screening appointment, or, you may return at a later date. If ICON does not have your medical records on file, you may need to provide medical records at screening.
For more information, see below.
Qualified participants may be compensated up to $10,760 for time and travel.
If you qualify to participate in the study, your participation will vary in length from approximately 71 to 134 days (depending upon dose) plus a screening period of 2 to 28 days.
You will need to attend:
|Clinical Study Identifier||TX231611|
|Last Modified on||23 November 2020|
Select a piece of text and start making personal notes.
You have contacted , on
Your message has been sent to the study team at ,
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.Learn more
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.Learn more
Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.Learn more
Congrats! You have your own personal workspace now.